Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chroma: Next Generation UK Biotech

This article was originally published in Start Up

Executive Summary

Recent M&A activity may have led to fewer top ranking UK biotech firms, but far from weakening the sector, it's actually providing opportunities for a newer generation of companies. Chroma Therapeutics Ltd. provides a good illustration of how experienced UK management talent is moving to lead younger, often private firms.

You may also be interested in...

HDAC Inhibitor Mysteries Remain As Candidates Advance

With more than a dozen candidates in the clinic and a range of indications expanding outside oncology, the histone deacetylase inhibitor class could be poised to make major inroads. But much remains to be learned about the activity, and companies are scrambling to find biomarkers.

Triggering Transcription: Seemingly Inactive Genes are On, but 'Stuck in Neutral'

Interest in gene regulatory networks is white hot, encompassing topics as wide ranging as reprogramming skin cells to give them characteristics of embryonic stem cells to the successful development of HDAC inhibitors. Now a research team has shown that many important regulatory genes in adult cells aren't switched off, as had been believed. They're primed to make protein, but something is stopping transcription--possibly a set of master signals that could be modulated with small molecules.

Ex-Shire Team Builds New Euro-Specialty Group

Archimedes joins a growing new generation of pan-European specialty pharma, highlighting the need for a single commercial partner across Europe and the increasing alternatives to big and mid-sized pharma.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts